In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


European Consolidation: Serious Competition for Big Pharma?

Executive Summary

Merck KGAA surprised observers when it announced the €10.6 billion takeover of Europe's biggest biotech, Serono. There was more consolidation to come. That same day, the Danish pharmaceutical group Nycomed Group said it would acquire Altana Pharma for about €4.5 billion in cash. Only a couple days later, UCB SA entered the fray with the acquisition of Schwarz Pharma AG for €4.2 billion in cash and stock. Can these bulked up companies present serious competition for Big Pharma on the licensing front?

You may also be interested in...

Can Merck Serono Bounce Back?

Merck KGAA’s $13 billion acquisition of Serono in 2006 created an unwieldy pharmaceutical organization further hobbled by expensive clinical setbacks. Seven years later, driven by new leadership, it is in the midst of an overdue transformation.

UCB Bets on Focus, Not Diversification

In contrast to some Big Pharmas, mid-sized UCB has shifted from a diversified to a very focused business model. That means it's relying heavily on commercial success for its three newest drugs. If the new products take off, UCB could by 2012 be delivering stronger earnings growth than its more diversified peers, just as some of them begin to face the worst of their patent cliffs. But it has little room to maneuver if even one of these disappoints.

Schering-Plough Adds to Pipeline with Organon Acquisition

In a bold move it says will bolster its late-stage pipeline and provide necessary scale in sales and biologics manufacturing, Schering-Plough Corp. is acquiring the CNS and women's health specialist Organon BioSciences from Dutch conglomerate Akzo Nobel for $14.4 billion. For the acquisition to be a success, SP will have to find value where others have not--specifically in Organon's Phase III schizophrenia treatment asenapine, which was handed back to the company by Pfizer after disappoinging clinical results.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts